LINC01136 Facilitates the Progression of HBV-Related Hepatocellular Carcinoma by Regulating the miR-140-5p/JAG1 Axis

Authors: Zhang, Xiaofei; Chen, Ran; Wang, Can; Yang, Nan; Liu, Fang

Source journal: Journal of medical virology (2026-11-01)

DOI: 10.1002/jmv.71207

Abstract

Hepatocellular carcinoma (HCC) represents highly aggressive tumor with poor prognosis, and hepatitis B virus (HBV) infection constitutes its primary etiological factor. To investigate the expression profiles, biological functions, and molecular regulatory mechanisms of long non-coding RNA LINC01136 in HBV-associated HCC (HBV-HCC), and to elucidate the role of the LINC01136/miR-140-5p/JAG1 axis in the malignant progression of HBV-HCC. Clinically, 130 HBV-HCC samples were collected to analyze the association between LINC01136 expression and clinicopathological parameters, as well as prognosis. Cellular functional assays, dual-luciferase reporter assays, RIP assays, and rescue assays were employed to validate the molecular targeting and regulatory relationships. LINC01136 is overexpressed in HBV-HCC tissues and cells and acts as an independent risk predictor for patient prognosis. Knockdown of LINC01136 inhibits malignant behaviors and promotes apoptosis in HCC cells. Mechanistically, LINC01136 functions as a ceRNA for miR-140-5p, thereby upregulating the downstream gene JAG1 and driving HBV-HCC progression. LINC01136 drives HBV-HCC progression via the miR-140-5p/JAG1 pathway, positioning it as a promising biomarker for predicting patient outcome and a potential therapeutic target.

Read the full text

Related topics

Related open access articles

Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.